UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 or 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of: ~~August~~September 2025

Commission File Number: 001-40207

Waldencast plc

(Translation of Registrant’s name into English)

81 Fulham Road

London, SW3 6RD

United Kingdom

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

~~Waldencast~~Indicate ~~Announces~~by ~~Strong~~check ~~Progress~~mark onif ~~Business~~the ~~Priorities~~registrant ~~for~~is H1submitting ~~2025~~the ~~and~~Form ~~Initiatives~~6-K toin ~~Drive~~paper ~~Transformation~~as permitted by Regulation S-T Rule 101(b)(1): ☐

OnIndicate ~~August 18,~~by ~~2025,~~check ~~Waldencast~~mark ~~plc~~if ~~provided~~the ~~business~~registrant ~~and~~is ~~financial~~submitting ~~updates~~the byForm ~~way~~6-K ofin apaper ~~press~~as ~~release.~~permitted Aby ~~copy~~Regulation ofS-T ~~the~~Rule ~~press~~101(b)(7): ~~release is attached hereto as Exhibit 99.1.~~☐

~~The information in this Report on Form 6-K (including Exhibit 99.~~1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Press Release

On September 10, 2025, Waldencast plc (the “Company”) issued an announcement titled “Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand”, a copy of which is attached as Exhibit 99.1 to this Form 6-K.

The information in this report on Form 6-K (including Exhibit 99.1 hereto) (“Report”) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

EXHIBIT INDEX

EXHIBIT NO.						DESCRIPTION
99.1						~~Waldencast~~Company ~~plc~~announcement ~~press release,~~ dated ~~August~~September 1810, 2025, “Waldencast Announces FDA Approval of Obagi® saypha® MagIQ™ Injectable Hyaluronic Acid Gel Under the Obagi Medical Brand”

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, ~~the~~Waldencast ~~registrant~~plc has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Waldencast plc
		(Registrant)
Date: August 18, 2025	By:	/s/ Manuel Manfredi
Date: September 10, 2025	By:	/s/ Manuel Manfredi
		Name:	Manuel Manfredi
		Title:	Chief Financial Officer and Principal Financial Officer

Filing Compare · Waldencast plc